Prestige Consumer Healthcare Inc. Stock

Equities

PBH

US74112D1019

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-21 pm EDT 5-day change 1st Jan Change
65.05 USD +0.54% Intraday chart for Prestige Consumer Healthcare Inc. -8.98% +6.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2025 * 1.13B Sales 2026 * 1.16B Capitalization 3.23B
Net income 2025 * 220M Net income 2026 * 234M EV / Sales 2025 * 3.59 x
Net Debt 2025 * 826M Net Debt 2026 * 579M EV / Sales 2026 * 3.28 x
P/E ratio 2025 *
14.7 x
P/E ratio 2026 *
13.8 x
Employees 570
Yield 2025 *
-
Yield 2026 *
-
Free-Float 88.58%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday MT
Transcript : Prestige Consumer Healthcare Inc., Q4 2024 Earnings Call, May 15, 2024
North American Morning Briefing : Traders Brace for CPI Inflation Data DJ
Prestige Consumer Healthcare Shares Fall Pre-Bell After Fiscal Q4 Miss MT
Prestige Consumer Healthcare Fiscal Q4 Adjusted Earnings, Revenue Drop; Fiscal 2025 Outlook Set; Shares Fall After Hours MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q4 Revenue $277M, vs. Street Est of $287.4M MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q4 EPS $1.02, vs. Street Est of $1.14 MT
Prestige Consumer Healthcare Inc. announces an Equity Buyback for $300 million worth of its shares. CI
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Prestige Consumer Healthcare Inc. Provides Earnings Guidance for the Fiscal Year 2025 CI
Prestige Consumer Healthcare Inc. authorizes a Buyback Plan. CI
Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing MT
Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing MT
Prestige Consumer Healthcare Insider Sold Shares Worth $368,184, According to a Recent SEC Filing MT
Prestige Consumer Healthcare's Fiscal Q3 Earnings, Revenue Increase; Raises 2024 Earnings Guidance; Shares Gain MT
More news

Latest transcript on Prestige Consumer Healthcare Inc.

1 day+0.08%
1 week-8.23%
Current month-9.84%
1 month-7.13%
3 months-5.90%
6 months+9.94%
Current year+5.68%
More quotes
1 week
63.00
Extreme 63
67.34
1 month
63.00
Extreme 63
72.13
Current year
57.95
Extreme 57.9497
75.31
1 year
52.90
Extreme 52.9
75.31
3 years
48.51
Extreme 48.51
75.31
5 years
27.40
Extreme 27.4
75.31
10 years
26.25
Extreme 26.25
75.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 10-12-05
Director of Finance/CFO 49 16-09-11
Chief Operating Officer 63 18-03-31
Members of the board TitleAgeSince
Director/Board Member 68 14-12-31
Director/Board Member 71 21-02-01
Director/Board Member 59 20-04-30
More insiders
Date Price Change Volume
24-05-21 65.05 +0.54% 304 878
24-05-20 64.7 +0.08% 322,549
24-05-17 64.65 -0.51% 473,777
24-05-16 64.98 -2.23% 534,647
24-05-15 66.46 -7.01% 824,553

Delayed Quote Nyse, May 20, 2024 at 04:00 pm EDT

More quotes
Prestige Consumer Healthcare Inc. is consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. It operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
64.7 USD
Average target price
73.5 USD
Spread / Average Target
+13.60%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW